https://orcid.org/0000-0001-6534-7361
References
- Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians. 1975;88:70–86.
- Tkachenko E, Steuer AB, Lo K, et al. Mycophenolate mofetil for eosinophilic fasciitis: a retrospective analysis from 3 tertiary care centers. JAMA Dermatol. 2020;156(5):595–597.
- Mango RL, Bugdayli K, Crowson CS, et al. Baseline characteristics and long-term outcomes of eosinophilic fasciitis in 89 patients seen at a single center over 20 years. Int J Rheum Dis. 2020;23(2):233–239.
- Tull R, Hoover WD, III De Luca JF, et al. Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission. Drugs Context. 2018;7:212529.
- Pituch-Noworolska A, Mach-Tomalska H, Szaflarska A, et al. Shulman disease (eosinophilic fasciitis) in X-linked agammaglobulinemia. Pol J Pathol. 2016;67(2):183–188.
- Loupasakis K, Derk CT. Eosinophilic fasciitis in a pediatric patient. J Clin Rheumatol. 2010;16(3):129–131.
- Drosou A, Kirsner RS, Welsh E, et al. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg. 2003;7(5):382–386.
- Chan KK, Magro C, Shoushtari A, et al. Eosinophilic fasciitis following checkpoint inhibitor therapy: four cases and a review of literature. Oncologist. 2020;25(2):140–149.
- Chan WH, Lewis DJ, Kim EJ, et al. Generalized morphea/eosinophilic fasciitis overlap after epoxy exposure. JAAD Case Rep. 2018;4(2):175–178.
- Strathie Page SJ, Tait CP. Mycophenolic acid in dermatology a century after its discovery. Australas J Dermatol. 2015;56(1):77–83.